forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Market Size, Share GLP-1 Market Size, Scope, Forecast

Majumdar, K

You may have heard about both medications and wondered which one is right for you

In anesthesia-stratified analysis among GLP-1 RA users, those receiving MAC/MS had higher odds of hospitalization compared with GA (OR 1.87, 95% CI 1.232.85, p = 0.003), whereas other outcomes were not significant

Individual responses vary considerably, and what works well for one patient may not be optimal for another

Retatrutide is not yet licensed by the MHRA or EMA and remains unavailable outside approved clinical trials in the UK

No, microdosing below the 2.5 mg starting dose is not FDA-approved and represents off-label use without clinical validation for safety or efficacy